TRT Access in Australia

Quick Reference Card

Overview / What Is TRT Access in Australia?

The Basics

Getting access to testosterone replacement therapy in Australia is a tale of two systems. On one side, there is the Pharmaceutical Benefits Scheme (PBS), the government program that subsidises medications for Australians who meet strict eligibility criteria. On the other side, there is a growing network of private telehealth clinics that offer faster access with more flexibility, but at a higher personal cost.

For men experiencing symptoms of low testosterone, the journey typically starts with a visit to a GP. The GP can order blood tests and, if the results point toward testosterone deficiency, will refer the patient to a specialist. In Australia, testosterone prescribing for PBS subsidy requires involvement of an endocrinologist, urologist, or Fellow of the Australasian Chapter of Sexual Health Medicine. This specialist-initiated model means that some men face significant waiting times before they can begin treatment.

One of the most distinctive features of the Australian system is its diagnostic threshold. To qualify for PBS-subsidised testosterone, a man generally needs a total testosterone level below 6 nmol/L (approximately 173 ng/dL), confirmed on two separate morning blood tests. This is considerably lower than the thresholds used in other countries. The US Endocrine Society and AUA use approximately 300 ng/dL (10.4 nmol/L) as their diagnostic threshold. The British Society for Sexual Medicine uses 12 nmol/L (~346 ng/dL). This means that a man with a testosterone level of 8 nmol/L (about 231 ng/dL) would qualify for treatment in the US and UK but would not qualify for PBS-subsidised treatment in Australia.

This gap has driven the growth of private TRT clinics across Australia, particularly telehealth services that can reach men in every state and territory. These clinics typically use diagnostic thresholds closer to international guidelines and offer formulations not available through the PBS, such as testosterone enanthate and cypionate for self-injection at home.

Understanding both pathways, their costs, their limitations, and the regulatory framework around them is essential for any Australian man considering testosterone therapy.

The Science

Australia's approach to testosterone prescribing is guided primarily by the Endocrine Society of Australia (ESA) Position Statement on testosterone prescribing (Yeap et al., MJA 2016) and resources from Healthy Male (Andrology Australia), the government-funded national men's health organization [1][2].

The ESA position statement distinguishes pathological hypogonadism, which requires identification of a hypothalamic, pituitary, or testicular disorder, from functional or age-related testosterone decline. The ESA explicitly states that "in the absence of hypothalamic, pituitary or testicular disorders, testosterone therapy is not justified in older men" [1]. This position is notably more conservative than US and European guidelines, which allow for treatment of symptomatic testosterone deficiency regardless of whether a specific pathological cause is identified.

Testosterone is regulated in Australia under the Therapeutic Goods Act 1989, administered by the TGA (Therapeutic Goods Administration). All testosterone products must be registered on the Australian Register of Therapeutic Goods (ARTG) before they can be supplied. Testosterone is classified as a Schedule 4 (Prescription Only Medicine) nationally, but several states and territories additionally classify it as a Schedule 8 (Controlled Drug), imposing additional prescribing and record-keeping requirements [3].

The PBS changes implemented in April 2015 tightened eligibility criteria, lowering the qualifying testosterone level from 8 nmol/L to 6 nmol/L and requiring specialist involvement for all new PBS prescriptions. Analysis of the impact showed that PBS-subsidised prescriptions declined, but total testosterone use did not. The proportion of prescriptions funded by PBS dropped from 86% to 66%, indicating that many men shifted to private prescriptions at full cost [4].

Medical / Chemical Identity

Testosterone replacement therapy in Australia uses exogenous testosterone in formulations registered on the ARTG. The regulatory and product landscape differs from other jurisdictions.

Australian Legal Classification:

• Therapeutic Goods Act 1989: Prescription Only Medicine (Schedule 4)
• State/territory poisons legislation: Schedule 8 (Controlled Drug) in several jurisdictions
• Import control: Border-controlled substance; import permit required from Office of Drug Control (ODC)
• Regulatory body: TGA (Therapeutic Goods Administration)

TGA-Registered Testosterone Products (ARTG):

Products NOT readily available in Australia:

• Testosterone cypionate (Depo-Testosterone): Available through compounding pharmacies and some private clinics, not TGA-registered as a standalone product
• Natesto (nasal testosterone), Jatenzo/Tlando/Kyzatrex (oral testosterone), Xyosted (auto-injector), Testopel (pellets): US formulations not available in Australia

Mechanism of Action / Pathophysiology

The Basics

Understanding TRT access in Australia requires some context about why testosterone deficiency occurs. Testosterone deficiency (called androgen deficiency or hypogonadism in medical terminology) happens when the body does not produce enough testosterone. This can result from problems with the testes themselves (primary hypogonadism), problems with the brain signals that tell the testes to produce testosterone (secondary hypogonadism), or a combination of both.

The Endocrine Society of Australia emphasises that having a lower-than-normal testosterone level does not automatically mean you have androgen deficiency. Low testosterone can be caused by weight gain, sleep disorders, chronic illness, medications (particularly opioids), and other reversible factors. Addressing these underlying causes may restore testosterone levels without medication [2].

The Science

The ESA Position Statement distinguishes three categories: primary hypergonadotropic testosterone deficiency (testicular failure, low testosterone with elevated LH/FSH), secondary hypogonadotropic testosterone deficiency (hypothalamic-pituitary dysfunction, low testosterone with low or inappropriately normal LH/FSH), and impaired action or suppression of testosterone by medications [1].

Diagnostic assessment requires serum testosterone measurement between 7am and 11am, on at least two occasions, preferably four weeks apart. LH and FSH measurements are necessary to differentiate primary from secondary causes. For men with total testosterone below 5.2 nmol/L and low LH/FSH, prolactin measurement is required to exclude hyperprolactinaemia and pituitary pathology, with MRI referral indicated [1].

Reference intervals using mass spectrometry in Australian populations include 10.4-30.1 nmol/L for young men (21-35 years) with normal reproductive function, and 6.4-25.7 nmol/L for very healthy men aged 70-89 years [1].

Pathway & System Visualization

Pharmacokinetics / Hormone Physiology

The Basics

The testosterone products available in Australia fall into two main categories: topical formulations (gels and creams) applied daily, and injections given at varying intervals. Each has different characteristics that affect how stable testosterone levels remain between doses.

Reandron (testosterone undecanoate 1000mg) is the most commonly prescribed TRT formulation in Australia via the PBS. It is a long-acting injection given every 10 to 14 weeks by a healthcare professional. It provides relatively stable levels for most of the interval, but some men notice a drop in energy and mood toward the end of each cycle.

Testogel and AndroForte 5 are daily-applied topical formulations that provide steady levels when used consistently. The main considerations are application technique, drying time, and the risk of transferring testosterone to partners or children through skin contact.

Private clinics in Australia commonly prescribe testosterone enanthate or cypionate, which can be self-injected weekly or twice weekly for more stable blood levels. These formulations are not PBS-subsidised.

The Science

The pharmacokinetic profiles of Australian-available testosterone formulations differ meaningfully, with implications for symptom control and side effect management.

Testosterone undecanoate (Reandron 1000mg IM) has a terminal half-life of approximately 33.9 days. Following the initial loading dose protocol (second injection at 6 weeks, then every 10-14 weeks), steady-state concentrations are typically achieved by the third injection. Trough levels should be measured immediately before the next scheduled injection [5].

Testosterone gel (Testogel 1%) achieves steady-state serum concentrations within 2-3 days of daily application. Absorption through the skin produces relatively flat pharmacokinetic profiles with less peak-to-trough variation compared to injectable formulations. Application to the shoulders and upper arms yields optimal absorption [6].

Testosterone enanthate and cypionate (available through private prescription or compounding) have elimination half-lives of approximately 4.5 and 8 days respectively, with peak concentrations typically reached 24-72 hours post-injection [7].

Research & Clinical Evidence

The Basics

The most important study for understanding TRT safety is the TRAVERSE trial, published in 2023. This was the largest randomised controlled trial ever designed specifically to assess whether testosterone therapy increases the risk of heart attacks and strokes. It enrolled 5,246 men aged 45 to 80 who already had cardiovascular disease or were at high risk for it. The result: testosterone therapy did not increase the rate of major cardiovascular events compared to placebo over an average of 33 months of follow-up [8].

This finding was significant because earlier, smaller studies had raised concerns about potential cardiovascular risks with testosterone. The TRAVERSE trial provided the most robust evidence to date that TRT is not associated with increased cardiovascular risk in appropriately selected men with hypogonadism.

The TRAVERSE trial did find small increases in atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone group. These were secondary findings, but they reinforce the importance of ongoing monitoring during treatment [8].

The Science

The TRAVERSE trial (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men) randomised 5,246 men aged 45-80 with hypogonadism (two fasting testosterone levels < 300 ng/dL) and preexisting or high risk for cardiovascular disease to 1.62% testosterone gel or placebo. The primary composite endpoint of MACE (cardiovascular death, nonfatal MI, nonfatal stroke) showed non-inferiority of testosterone therapy (HR 0.96, 95% CI: 0.78-1.17), with the upper bound below the prespecified non-inferiority margin of 1.20. Mean follow-up was 33 months [8].

A meta-analysis by Fallara et al. (2022) including 179,631 subjects found no effect of testosterone replacement therapy on cardiovascular events and found that TRT protected against all-cause mortality (pooled HR 0.70, 95% CI: 0.54-0.90) [9].

An individual participant data meta-analysis by Hudson et al. (2022) also found no increase in adverse cardiovascular events with testosterone treatment in men with androgen deficiency [10].

Evidence & Effectiveness Matrix

Categories not scored (insufficient data for country-access guide): Anxiety & Stress Response, Cognitive Function, Metabolic Health, Sleep Quality, Prostate Health, Skin & Hair, Gynecomastia & Estrogen, Fluid Retention & Edema.

Benefits & Therapeutic Effects

The Basics

For men with confirmed testosterone deficiency, TRT can improve quality of life across several domains. The most commonly reported benefits include improved energy levels, better mood and emotional stability, increased libido and sexual function, and gradual improvements in body composition (more muscle, less fat).

These benefits are well-established for men with pathological hypogonadism. Healthy Male (Andrology Australia) states that "for men who actually have low testosterone, TRT is a game-changer" while cautioning that for others "it can be unnecessary and even dangerous" [2].

The Australian community consistently reports that the single most noticeable early improvement is energy. Many men describe years of fatigue and low motivation resolving within weeks of starting therapy.

The Science

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials in 790 men aged 65 and older with testosterone levels below 275 ng/dL, demonstrated significant improvements in sexual desire and activity (Sexual Function Trial), physical activity (Physical Function Trial), and mood/depressive symptoms (Vitality Trial) with 12 months of testosterone gel therapy [11].

A meta-analysis by Corona et al. (2016) found that testosterone therapy in hypogonadal men was associated with significant improvements in body composition (reduced fat mass, increased lean mass), sexual function, and quality of life measures [12].

Reading about the potential benefits gives you a framework for what to look for. Tracking whether those benefits are actually showing up in your own experience turns hope into evidence. Doserly lets you monitor the specific outcomes that matter most to you, from energy and libido to mood and body composition, building a personal record of how your testosterone therapy is working.

When it's time for your next provider appointment, you'll have concrete data showing which symptoms have improved, which haven't changed, and when shifts started happening. That kind of detail makes follow-up conversations more productive and dose adjustments more precise.

Risks, Side Effects & Safety

The Basics

Like any medical treatment, TRT has risks and side effects that need to be understood and monitored. The most common side effects include acne and oily skin, injection site reactions (for injectables), fluid retention (particularly in the first few weeks), and testicular shrinkage (because the external testosterone signals the brain to reduce its own production).

The most important safety concern that Australian providers monitor is polycythemia, an increase in red blood cell count that thickens the blood and can increase the risk of blood clots. Regular blood tests checking haematocrit levels are essential, and if haematocrit exceeds 54%, your provider will typically reduce the dose, increase injection frequency, change to a transdermal formulation, or arrange therapeutic phlebotomy (blood removal).

Regarding heart risk, the TRAVERSE trial (the largest cardiovascular safety trial for TRT) found no increased risk of heart attack, stroke, or cardiovascular death in men on testosterone compared to placebo. Specifically, the rate of major cardiovascular events was essentially the same between groups (hazard ratio 0.96) over an average of 33 months of follow-up. In absolute terms, MACE events occurred in 7.0% of the testosterone group compared to 7.3% of the placebo group [8].

TRT also suppresses sperm production, which is an important consideration for men who may want to have children in the future (covered in detail in Section 14).

The Science

Polycythemia/Erythrocytosis: Testosterone stimulates erythropoiesis via EPO receptor upregulation and direct effects on haematopoietic stem cells. Ohlander et al. (2016) reported that men on TRT have a 315% greater risk of developing erythrocytosis (haematocrit > 0.52) compared to controls. Risk is higher with intramuscular injection than transdermal formulations, and higher with less frequent dosing (greater peak-to-trough variation). The Australian threshold for clinical intervention is haematocrit > 54% (0.54), consistent with Endocrine Society guidelines [13][5].

Cardiovascular Safety: The TRAVERSE trial demonstrated non-inferiority of testosterone gel vs placebo for the primary MACE composite endpoint (HR 0.96, 95% CI: 0.78-1.17) in a high-cardiovascular-risk population. Secondary findings included increased incidence of atrial fibrillation (HR 1.26, 95% CI: 0.91-1.74), pulmonary embolism (HR 1.92, 95% CI: 1.13-3.25), and acute kidney injury (HR 1.28, 95% CI: 1.00-1.64) in the testosterone group [8].

Prostate Safety: Current evidence does not support a causal link between testosterone therapy at physiological replacement doses and prostate cancer initiation. PSA monitoring is standard practice in Australia, with referral to urology recommended for PSA increases > 1.4 ng/mL within 12 months or absolute PSA > 4.0 ng/mL [2].

Contraindications (Australian guidelines): Active or suspected prostate cancer, male breast cancer, haematocrit > 54% at baseline, uncontrolled heart failure, desire for near-term fertility, untreated severe obstructive sleep apnoea [1][2].

Dosing & Treatment Protocols

The Basics

In Australia, the most commonly prescribed TRT through the PBS is Reandron (testosterone undecanoate), given as an injection every 10 to 14 weeks by a healthcare professional. This long-acting formulation is convenient in that it requires infrequent visits, but some men find that their energy and mood decline in the weeks before their next injection.

Testosterone gels (Testogel, AndroForte) are applied daily and provide more stable testosterone levels throughout the day. They require consistent daily application and attention to transfer precautions.

Through private clinics, testosterone enanthate or cypionate injections (typically 100-200mg weekly or split into twice-weekly doses) are increasingly popular. These shorter-acting formulations allow self-injection at home and, when used at higher frequencies, can produce very stable blood levels with fewer peaks and troughs.

Dosing is always individualised. Treatment typically starts at a conservative dose, with adjustments based on trough testosterone levels and symptom response at follow-up visits.

The Science

Standard Australian TRT dosing protocols include:

Target trough testosterone levels in Australia are typically 15-30 nmol/L (430-865 ng/dL) at trough for injectable formulations. Endocrine Society guidelines recommend maintaining levels in the mid-normal range for the patient's age [5][7].

What to Expect (Timeline)

Days 1-7: Possible initial energy or mood lift (partly placebo effect). Injection site soreness (if IM). Minor skin irritation (if transdermal). No significant hormonal changes expected this early.

Weeks 2-4: Libido changes are often the first noticeable effect. Some men report improved energy and motivation. Mood may begin to shift. For gel/cream users, levels should be reaching steady state.

Months 1-3: Sexual function improvements become more apparent. Initial body composition changes may begin. Mood stabilisation is typically noticeable by this point. Haematocrit begins rising. First follow-up blood test typically occurs at 6-12 weeks.

Months 3-6: Body composition changes become more visible (reduced body fat, increased lean mass). Strength improvements are noticeable. Mood and energy stabilise. Honeymoon period may start to normalise. Reandron patients will have had their third or fourth injection by this point.

Months 6-12: Full sexual function benefits. Significant body composition changes. Bone density improvements begin to be measurable. Annual review and ongoing monitoring established.

Ongoing: Annual review with provider. Dose reassessment based on symptoms and blood work. Continued haematocrit, PSA, and testosterone monitoring.

Individual response varies widely. Not all symptoms resolve with TRT alone. Dose adjustment is common, and some benefits take months to fully manifest.

Fertility Preservation & HPG Axis

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis. When external testosterone is administered, the brain detects adequate testosterone levels and reduces its signalling (LH and FSH) to the testes. Without this stimulation, intratesticular testosterone drops dramatically, impairing spermatogenesis. Studies show that up to 40-60% of men on TRT develop azoospermia (zero sperm) within 6 months, with the remainder typically showing severe oligospermia [14].

Before starting TRT in Australia, men should discuss:

• Whether they plan to have children in the future
• Sperm banking as a precautionary measure
• HCG co-therapy to maintain intratesticular testosterone and spermatogenesis (500-1000 IU, 2-3 times weekly)
• SERMs (clomiphene, enclomiphene) as potential alternatives that raise endogenous testosterone without suppressing spermatogenesis

Healthy Male states clearly: "If you are planning to try to have a child, your doctor won't prescribe testosterone therapy" [2].

Recovery of spermatogenesis after discontinuing TRT is possible but not guaranteed. Most men recover within 6-12 months, but some require up to 24 months, and a small percentage may not recover fully, particularly after prolonged use [15].

Interactions & Compatibility

Testosterone interacts with several medication classes:

• Anticoagulants (warfarin, DOACs): Testosterone may enhance anticoagulant effect; INR monitoring required
• Insulin and diabetes medications: Testosterone may improve insulin sensitivity, potentially requiring dose adjustment of diabetes medications
• Corticosteroids: Additive fluid retention
• 5-alpha reductase inhibitors (finasteride, dutasteride): Blocks DHT conversion, affects hair loss and prostate effects
• Opioids: Chronic opioid use suppresses the HPG axis and may be an underlying cause of low testosterone

Related Doserly guides:

• Testosterone Cypionate
• Testosterone Enanthate
• Testosterone Undecanoate Injectable (Aveed / Nebido)
• HCG
• Anastrozole
• Clomiphene Citrate
• Fertility Preservation on TRT

Decision-Making Framework

Making the decision to pursue TRT in Australia requires navigating a healthcare system with unique characteristics. Here is a practical framework for approaching the process.

Confirming the Diagnosis

Australian guidelines require at least two morning blood samples (drawn fasting, before 10am) showing low testosterone levels, combined with clinical symptoms. A single blood test or an afternoon sample is not sufficient for diagnosis. Total testosterone should be measured alongside LH, FSH, and SHBG at minimum [1][2].

When TRT May Be Appropriate

• Confirmed primary hypogonadism (testicular failure) with symptoms
• Confirmed secondary hypogonadism (pituitary/hypothalamic dysfunction) with symptoms, after ruling out reversible causes
• Klinefelter syndrome or other genetic conditions affecting testosterone production

When to Investigate Underlying Causes First

• Obesity (weight loss of 10% can increase testosterone by 2-3 nmol/L)
• Obstructive sleep apnoea (CPAP optimisation first)
• Opioid use (taper if possible)
• Chronic illness (treating the underlying condition may restore levels)
• Depression (distinguish cause from effect)

Choosing Your Pathway in Australia

PBS pathway: Best for men who meet the strict PBS criteria (testosterone < 6 nmol/L or 6-15 nmol/L with elevated LH), have an established pituitary or testicular disorder, and are comfortable with the available PBS formulations (primarily Reandron or gel).

Private clinic pathway: Better for men who have symptoms and testosterone levels in the 6-15 nmol/L range but do not meet PBS criteria, who want access to testosterone enanthate or cypionate for self-injection, or who prefer faster access and more frequent monitoring.

Questions to Ask Your Provider

• What were my testosterone levels on both morning blood draws?
• Is my hypogonadism primary or secondary? Has the underlying cause been investigated?
• What formulation do you recommend and why?
• What is the monitoring plan? How often will I have blood tests?
• What are the fertility implications, and should I consider sperm banking?
• Am I eligible for PBS-subsidised treatment?
• If not PBS-eligible, what is the expected ongoing cost?

Finding a Provider in Australia

• Endocrinologists: Available through GP referral. Specialist in hormonal disorders. Wait times can be significant through the public system.
• Urologists: Can assess and prescribe TRT, particularly relevant if prostate health is a concern.
• Sexual Health Physicians: Fellows of the Australasian Chapter of Sexual Health Medicine can provide PBS authority scripts.
• Private TRT Clinics: Telehealth services operating nationally. See Section Section 21 for a detailed breakdown.
• GPs: Can prescribe TRT on private prescription but cannot issue PBS authority scripts without specialist involvement. Quality of TRT knowledge varies significantly.

The best TRT decisions happen when you walk into your appointment prepared. Doserly helps you organize your symptom data, lab results, and questions ahead of time, so you can make the most of your consultation time and ensure nothing important gets forgotten.

The app generates appointment-ready summaries of your recent symptom trends, current protocol, hematocrit and PSA values, and any side effects you've logged. Instead of trying to recall three months of experience in a ten-minute appointment, you have a clear, organized record to share with your provider.

Administration & Practical Guide

Reandron (testosterone undecanoate 1000mg IM):
This injection must be administered by a healthcare professional (nurse, GP, or clinic staff) due to the large injection volume (4mL). It is given as a deep intramuscular injection into the gluteal muscle. The first two injections are 6 weeks apart, then every 10-14 weeks thereafter. Men cannot self-administer Reandron.

Testogel (1% testosterone gel):
Applied daily to clean, dry skin on the shoulders, upper arms, or abdomen. Allow 3-5 minutes drying time before covering with clothing. Avoid skin contact with partners or children for at least 2 hours after application. Wash hands thoroughly after application. Do not apply to genitals.

AndroForte 5 (5% testosterone cream):
When prescribed under PBS, applied to scrotal skin daily. When prescribed on private script, can be applied to torso. Follow prescribing instructions for application site.

Testosterone enanthate/cypionate (private prescription):
For intramuscular injection: 23-25 gauge needle, 1-1.5 inches, injected into vastus lateralis (outer thigh), ventrogluteal (hip), or deltoid. For subcutaneous injection: 27-30 gauge insulin syringe, 0.5 inches, injected into abdominal or thigh fat. Rotate injection sites. Warm the oil before injecting for easier flow.

All administration guidance is educational. Always follow your prescriber's specific instructions and the product's Consumer Medicine Information (CMI).

Monitoring & Lab Work

Pre-TRT Baseline Labs (Australian standard):

• Total testosterone (two fasting morning draws, before 10am)
• Free testosterone (calculated or measured)
• LH, FSH
• Oestradiol (estradiol)
• SHBG
• Prolactin (if secondary hypogonadism suspected)
• Full blood count (FBC) with haematocrit
• PSA (men over 40)
• Lipid panel
• Liver function tests
• Fasting glucose/HbA1c
• Thyroid function (TSH)

Follow-up Schedule:

• 6-12 weeks: Trough testosterone, haematocrit, oestradiol, symptom assessment
• 3 months: Full panel repeat, dose adjustment if needed
• 6 months: PSA, full panel repeat
• Ongoing (6-12 monthly): Haematocrit (priority), PSA (annually for men > 40), testosterone levels, oestradiol if symptomatic, lipid panel annually

Action Thresholds (per Australian guidelines):

• Haematocrit > 54%: Dose reduction, route change, or therapeutic phlebotomy
• PSA increase > 1.4 ng/mL in 12 months or absolute > 4.0 ng/mL: Urological referral
• Oestradiol: Monitor if symptomatic (gynecomastia, fluid retention); treat symptoms, not numbers

Estrogen Management on TRT

Testosterone aromatises to oestradiol (estradiol) via the aromatase enzyme, primarily in adipose tissue. This is a normal physiological process. Oestradiol is important for bone health, cardiovascular function, libido, and cognitive function in men.

Australian clinical guidelines do not recommend routine aromatase inhibitor (AI) use during TRT. Oestradiol monitoring is indicated only if symptoms suggest elevated oestrogen (gynecomastia, excessive fluid retention, emotional lability) [1][2].

Target oestradiol in Australian practice is typically guided by symptoms rather than specific numbers. Reference ranges of 70-180 pmol/L (19-49 pg/mL) are commonly cited, but clinical decisions should be based on symptom assessment.

The online men's health community places significant emphasis on oestradiol management and aromatase inhibitor use. Clinical guidelines do not support routine AI co-prescription with TRT. Excessive oestradiol suppression is associated with joint pain, decreased libido, adverse mood effects, and bone density loss.

Managing estrogen on TRT is about data, not guesswork. Doserly lets you track your estradiol lab values alongside the symptoms that might signal imbalance, whether that's water retention, nipple sensitivity, or mood changes, so you and your provider can make decisions based on the full picture rather than isolated data points.

If you're taking an aromatase inhibitor, the app logs every dose and correlates it with how you feel, helping you find the minimum effective approach. The goal is balanced estrogen, not crashed levels, and having tracked data makes it far easier to dial in the right strategy with your prescriber.

Stopping TRT / Post-Cycle Considerations

TRT is typically a long-term commitment. For men with primary hypogonadism (testicular failure), testosterone replacement is usually lifelong. For men with secondary hypogonadism, addressing underlying causes (weight loss, sleep apnoea treatment, opioid cessation) may restore endogenous production, potentially allowing TRT discontinuation.

When TRT is stopped, the HPG axis remains suppressed for weeks to months. Endogenous testosterone production may take 6-24 months to recover, and recovery to pre-TRT levels is not guaranteed.

Post-TRT recovery strategies discussed in the community include:

• HCG taper (1000-2000 IU every other day for 2-4 weeks, then taper)
• Clomiphene citrate (25-50mg daily for 4-8 weeks)
• Enclomiphene

These protocols are adapted from community practice and are not standardized in Australian clinical guidelines. Any TRT discontinuation should be managed under medical supervision.

The ESA Position Statement notes that men who were prescribed testosterone without a clear pathological indication may experience withdrawal symptoms when discontinuing, as the HPG axis has been suppressed by exogenous testosterone [4].

Special Populations & Situations

Obese Men

Weight loss alone can significantly increase testosterone levels. The ESA notes that 10% weight loss can raise testosterone by 2-3 nmol/L. In morbidly obese men, bariatric surgery or substantial weight loss can produce even larger increases. Australian guidelines recommend addressing obesity before initiating TRT for functional hypogonadism [1].

Men with Sleep Apnoea

TRT may exacerbate obstructive sleep apnoea. Australian guidelines recommend CPAP optimisation before and during TRT. Sleep study may be recommended before initiation [1][2].

Men with Cardiovascular Risk

The TRAVERSE trial provides reassurance of cardiovascular safety for TRT in men with hypogonadism and cardiovascular risk factors (HR 0.96 for MACE) [8]. Haematocrit monitoring is critical, as polycythemia increases thrombotic risk.

Older Men (> 65)

The distinction between age-related testosterone decline and true hypogonadism is central to the Australian approach. The ESA explicitly states that testosterone therapy is not justified in older men without hypothalamic, pituitary, or testicular disorders [1]. Lower starting doses are often appropriate.

Transgender Men (FTM)

Australia has a distinct informed consent pathway for transgender hormone therapy that operates somewhat separately from the standard TRT access pathway. Many states have specialised gender clinics, and GPs trained in informed consent can initiate testosterone for gender-affirming care. PBS access still requires specialist authority. Resources include TransHub (transhub.org.au) and AusPATH for finding knowledgeable providers.

Rural and Remote Australians

Telehealth TRT clinics have significantly improved access for men outside major cities. All major private TRT clinics operate nationally via video consultation. Medication can be shipped to remote locations, though blood test access may be limited.

Regulatory, Insurance & International

This is the primary content section for this country-access guide.

Australian Regulatory Framework

Therapeutic Goods Administration (TGA):
The TGA is Australia's regulatory authority for therapeutic goods, operating under the Therapeutic Goods Act 1989. All testosterone products must be registered on the Australian Register of Therapeutic Goods (ARTG) before they can be legally supplied. The TGA evaluates safety, quality, and efficacy of testosterone products and monitors post-market safety through adverse event reporting.

Scheduling Classification:
Testosterone is classified nationally as a Schedule 4 (Prescription Only Medicine) under the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP). Several states and territories additionally classify testosterone and other anabolic steroids under Schedule 8 (Controlled Drug), which imposes additional requirements for prescribing, dispensing, storage, and record-keeping. The practical implications include:

• Prescriptions must be issued by a registered medical practitioner
• Pharmacists must maintain records of Schedule 8 dispensing
• State-specific regulations govern storage, transport, and administration
• Private prescriptions may have dispensing limitations (e.g., maximum supply periods)

Office of Drug Control (ODC):
Testosterone is a border-controlled substance in Australia. Importing testosterone requires an import permit from the Office of Drug Control for each shipment and each substance/preparation type. A licence is not required, but a permit is mandatory. Travellers may enter Australia with a personal supply of up to 3 months under the traveller's exemption, provided they have a valid prescription and carry it with them.

Pharmaceutical Benefits Scheme (PBS)

The PBS is the Australian Government program that subsidises the cost of prescription medications for eligible patients. Testosterone is listed on the PBS under Authority Required provisions, meaning prescribers must obtain prior approval from Services Australia before the subsidy applies.

PBS Eligibility Criteria (Updated April 2015):

Prescriber requirements:
Patient must be treated by, or in consultation with, one of: a specialist urologist, an endocrinologist, a Fellow of the Australasian Chapter of Sexual Health Medicine; or have an appointment to be assessed by one of these specialists.

Biochemical requirements:
Androgen deficiency must be confirmed by at least two morning blood samples taken on different mornings:

1. Testosterone < 6 nmol/L (~173 ng/dL): Patient must have an established pituitary or testicular disorder.
2. Testosterone between 6-15 nmol/L with elevated LH: LH must be > 1.5 times the upper limit of the eugonadal reference range for young men, or > 14 IU/L, whichever is higher. Patient must NOT have an established pituitary or testicular disorder. The condition must NOT be due to age, obesity, cardiovascular diseases, infertility, or drugs. Patient must be aged 40 years or older.

Impact of 2015 PBS changes:

• Qualifying testosterone level lowered from 8 nmol/L to 6 nmol/L for Path 1
• All prescriptions require specialist involvement (new requirement)
• No "grandfather" clause for existing patients
• PBS-subsidised prescriptions declined, but total testosterone prescribing did not decrease; proportion of PBS-funded prescriptions dropped from 86% to 66% [4]
• In 2018: 33,615 patients received PBS-subsidised testosterone; total PBS expenditure was $13,079,019 [16]

PBS-Listed Formulations and Costs:

Not PBS-listed: Testosterone enanthate (Primoteston Depot), testosterone cypionate, compounded testosterone preparations.

Private Clinic Pathway

Private TRT clinics have grown significantly in Australia since the 2015 PBS changes. Most operate nationally via telehealth, making them accessible from any state or territory. They typically offer:

• Lower diagnostic thresholds: Many consider treatment for men with testosterone in the low-normal range (8-15 nmol/L) with symptoms, rather than requiring the PBS threshold of < 6 nmol/L
• More formulation options: Testosterone enanthate and cypionate available for self-injection
• Faster access: Typically 2-6 weeks from initial consultation to starting treatment, compared to months for public specialist referral
• Ongoing monitoring: Regular blood work review as part of the service

Major Australian TRT Clinics (2026):

Annual costs include consultations, blood work reviews, and medication. Medication is typically charged separately at $13-28 per mL of testosterone, depending on the clinic.

Medicare and Insurance

Medicare coverage:

• GP consultations are partially covered by Medicare (rebate typically $38-80 per standard consultation)
• Specialist consultations are partially covered with a GP referral (rebate typically $75-130)
• Pathology tests are generally bulk-billed (no out-of-pocket cost) when ordered by a GP or specialist
• PBS medications are subsidised at the rates listed above
• Private clinic consultations may attract Medicare rebates if the provider is a registered medical practitioner and the consultation is conducted appropriately

Private health insurance:

• Private health insurance does not typically cover the cost of testosterone medication or TRT clinic fees
• It may cover specialist consultations and hospital-related procedures (e.g., investigation of pituitary pathology)
• Extras cover may provide partial rebates for allied health services but not for TRT specifically

International Comparison

Travel Considerations

• Travelling within Australia: Carry a copy of your prescription. If on Schedule 8 medication, state-specific rules may apply to transport.
• Travelling internationally with testosterone: Carry a letter from your prescriber confirming your diagnosis and prescription, along with original labelled medication. Many countries classify testosterone as a controlled substance. Check destination country regulations before travel. The ODC traveller's exemption allows up to 3 months' personal supply on entry to Australia.
• Travelling to Australia with testosterone: Travellers may bring up to 3 months' personal supply under the traveller's exemption with a valid prescription. Larger quantities require an ODC import permit.

Compounding Pharmacies

Compounding pharmacies play an important role in Australian TRT access by preparing formulations not commercially available, including testosterone cypionate and customised cream concentrations. Compounded medications are not PBS-subsidised and are prescribed on private prescriptions. Quality and cost vary between compounding pharmacies. Some private TRT clinics partner with specific compounding pharmacies for medication supply.

Frequently Asked Questions

How do I get TRT in Australia?
Start by seeing a GP who can order morning fasting testosterone blood tests. If results confirm low testosterone (with symptoms), the GP can either prescribe on a private prescription or refer you to an endocrinologist, urologist, or sexual health physician for PBS-subsidised treatment. Alternatively, contact a private TRT telehealth clinic for an assessment.

Do I need to see a specialist to get testosterone in Australia?
For a private prescription, a GP can prescribe testosterone directly. For PBS-subsidised treatment, specialist involvement (endocrinologist, urologist, or sexual health physician) is required to obtain the PBS authority code.

What is the PBS threshold for testosterone in Australia?
The current PBS threshold is total testosterone below 6 nmol/L (approximately 173 ng/dL) on two separate morning blood tests, along with an established pituitary or testicular disorder. Men with testosterone between 6-15 nmol/L may qualify if they have elevated LH, are aged 40+, and the condition is not due to age, obesity, or other reversible causes.

Why is the Australian PBS threshold so much lower than other countries?
The Endocrine Society of Australia takes a more conservative position, distinguishing pathological hypogonadism (due to an identifiable disorder of the HPG axis) from functional or age-related testosterone decline. The PBS threshold is designed to subsidise treatment only for men with pathological hypogonadism, not age-related decline.

How much does TRT cost in Australia?
Through the PBS: approximately $25-31 per prescription (general patient charge) or $7 with a Health Care Card. Through private clinics: approximately $1,300-2,600 per year including consultations, blood work, and medication.

Can I self-inject testosterone in Australia?
Yes, through private clinics that prescribe testosterone enanthate or cypionate. Self-injection is not possible with Reandron (the PBS-listed long-acting injection), which must be administered by a healthcare professional due to its large volume.

Is testosterone legal in Australia?
Yes, testosterone is legal with a valid prescription from a registered Australian medical practitioner. It is illegal to possess or supply testosterone without a prescription. Importing testosterone requires an ODC permit.

Can I get TRT through telehealth in Australia?
Yes, most Australian private TRT clinics operate primarily via telehealth (video consultation), making them accessible from any state or territory. Several clinics offer national coverage.

What formulations are available in Australia?
PBS-listed: Reandron (T undecanoate IM), Testogel (gel), AndroForte 5 (cream). Through private prescription: testosterone enanthate, testosterone cypionate (including compounded). Products available in the US but not Australia include Natesto, Jatenzo, Xyosted, Testopel, and Androderm patches (limited availability).

Does Medicare cover TRT?
Medicare covers part of the consultation costs (GP and specialist visits) through rebates. Medication costs are covered through the separate PBS program for eligible patients. Private clinic fees may attract Medicare rebates if the clinician is a registered medical practitioner.

What blood tests do I need before starting TRT in Australia?
At minimum: total testosterone (two fasting morning draws before 10am), LH, FSH, SHBG, full blood count with haematocrit, PSA (men over 40), and liver function. Additional tests recommended include oestradiol, prolactin, thyroid function, lipid panel, and fasting glucose.

Can I travel internationally with my testosterone prescription?
Yes, but carry a letter from your prescriber confirming your diagnosis and prescription, and bring the original labelled medication. Check the destination country's regulations regarding controlled substances. When returning to Australia, the traveller's exemption allows up to 3 months' personal supply.

Myth vs. Fact

Myth: TRT is illegal in Australia.
Fact: TRT is legal and medically supported in Australia when prescribed by a registered medical practitioner for confirmed testosterone deficiency. What is illegal is possession or supply of testosterone without a valid prescription, or importing it without an ODC permit.

Myth: You need testosterone levels below 6 nmol/L to get TRT in Australia.
Fact: The 6 nmol/L threshold applies specifically to PBS-subsidised treatment. GPs can prescribe testosterone on a private prescription, and private clinics commonly treat men with levels in the low-normal range (8-15 nmol/L) who have symptoms. The PBS threshold is not a clinical treatment threshold; it is a subsidy eligibility threshold.

Myth: TRT causes heart attacks.
Fact: The TRAVERSE trial (n=5,246, mean follow-up 33 months) found no increased risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) with testosterone therapy compared to placebo (HR 0.96, 95% CI: 0.78-1.17). Earlier observational studies raised concerns, but the TRAVERSE trial, the largest prospective RCT designed for cardiovascular outcomes, did not confirm those concerns [8].

Myth: TRT causes prostate cancer.
Fact: Current evidence does not support a causal link between testosterone therapy at physiological replacement doses and prostate cancer initiation. PSA monitoring is standard practice during TRT, and any significant PSA rise warrants urological evaluation, but TRT itself does not appear to cause prostate cancer [17].

Myth: Once you start TRT, you can never stop.
Fact: Whether TRT is permanent depends on the underlying cause. Men with primary hypogonadism (testicular failure) will typically need lifelong treatment. Men with secondary hypogonadism may be able to discontinue TRT if the underlying cause (obesity, sleep apnoea, medication) is addressed. Recovery of endogenous testosterone production is possible but variable and not guaranteed [1].

Myth: TRT will make you permanently infertile.
Fact: TRT suppresses sperm production (often to azoospermia), but this is usually reversible after discontinuation. Most men recover spermatogenesis within 6-12 months of stopping TRT. Recovery can be accelerated with HCG or SERM therapy. However, recovery is not guaranteed in all cases, and sperm banking before starting TRT is recommended for men who may want biological children [15].

Myth: All Australian TRT clinics are the same.
Fact: There is significant variation in quality, cost, and approach among Australian TRT clinics. Some provide comprehensive monitoring and evidence-based care; others have been criticised for inadequate follow-up. Look for clinics that require comprehensive baseline blood work, discuss fertility, provide a structured monitoring plan, and have accessible prescribing physicians.

Myth: You only need one blood test to diagnose low testosterone.
Fact: Australian guidelines require at least two fasting morning blood tests (drawn before 10am) showing low testosterone levels on separate occasions. A single test, or a test drawn in the afternoon, is not sufficient for diagnosis due to natural diurnal variation in testosterone levels [1][2].

Sources & References

Clinical Guidelines:

[1] Yeap BB, Grossmann M, McLachlan RI, et al. Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy. Medical Journal of Australia. 2016;205(4):173-178.

[2] Healthy Male (Andrology Australia). Testosterone replacement therapy: What is it and do you need it? https://healthymale.org.au/health-article/what-is-testosterone-replacement-therapy

[3] Therapeutic Goods Administration (TGA). Australian Register of Therapeutic Goods. Testosterone product registrations. https://www.tga.gov.au

Government/Regulatory Sources:

[4] Handelsman DJ. Pharmacoepidemiology of testosterone: Impact of reimbursement policy on curbing off-label prescribing. Pharmacoepidemiology and Drug Safety. 2020.

[5] Endocrine Society. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2018;103(5):1715-1744.

[6] Testogel Product Information. Therapeutic Goods Administration (TGA) approved prescribing information. Besins Healthcare Australia Pty Ltd.

[7] Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. Journal of Urology. 2018;200(2):423-432.

Landmark Trials:

[8] Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. New England Journal of Medicine. 2023;389(2):107-117.

Systematic Reviews & Meta-Analyses:

[9] Fallara G, et al. Cardiovascular morbidity and mortality in men: findings from a meta-analysis on the time-related measure of risk of exogenous testosterone. Journal of Sexual Medicine. 2022.

[10] Hudson J, et al. Adverse cardiovascular events and mortality in men during testosterone treatment: an individual participant data meta-analysis. Lancet Healthy Longevity. 2022.

[11] Snyder PJ, Bhasin S, Cunningham GR, et al. Lessons from the Testosterone Trials. Endocrine Reviews. 2018;39(3):369-386.

[12] Corona G, Giagulli VA, Maseroli E, et al. Testosterone supplementation and body composition: results from a meta-analysis study. Journal of Endocrinological Investigation. 2016;39(9):967-981.

Observational Studies:

[13] Ohlander SJ, Varghese B, Ganesan V. Erythrocytosis and polycythemia secondary to testosterone replacement therapy in the aging male. Sexual Medicine Reviews. 2016;4(4):304-312.

[14] Patel AS, Leong JY, Ramos L, Ramasamy R. Testosterone is a contraceptive and should not be used in men who desire fertility. World Journal of Men's Health. 2019;37(1):45-54.

[15] Wenker EP, Dupree JM, Langille GM, et al. The use of HCG-based combination therapy for recovery of spermatogenesis after testosterone use. Journal of Sexual Medicine. 2015;12(6):1334-1337.

Government/Institutional Sources:

[16] Pharmaceutical Benefits Scheme (PBS). Drug Utilisation Sub-Committee (DUSC) Report: Testosterone. February 2020.

[17] Endocrine Society. Clinical Practice Guideline: Testosterone therapy in men with hypogonadism. 2018. Recommendation on prostate safety.

Related Guides & Cross-Links

Same Category (Country Access Guides)

• TRT Access in the United States
• TRT Access in the United Kingdom
• TRT Access in Canada
• TRT Access in the European Union

Related Treatment Options

• Testosterone Cypionate
• Testosterone Enanthate
• Testosterone Undecanoate Injectable (Aveed / Nebido)
• Testosterone Gel (AndroGel)
• Compounded Testosterone Cream

Treatment Overviews

• Testosterone Injections Guide
• Testosterone Gels & Topicals Guide
• TRT for Beginners
• TRT Blood Work Guide
• Fertility Preservation on TRT
• Estrogen Management on TRT

Conditions & Causes

• Primary Hypogonadism
• Secondary Hypogonadism
• Late-Onset Hypogonadism
• Obesity-Related Hypogonadism

Ancillary Medications

• HCG
• Clomiphene Citrate
• Enclomiphene Citrate
• Anastrozole

Educational Resources

• The TRAVERSE Trial Explained
• TRT Myths vs Facts
• Stopping TRT & Post-Cycle Recovery
• Natural Testosterone Optimization